Intellia Therapeutics Tops Gene Editing Stock Losses

Intellia Therapeutics leads losses among gene editing stocks after reporting a Q4 2025 net loss of US$0.83 per share on US$23 million revenue, with trailing 12-month losses hitting US$412.7 million. The company invests heavily in its CRISPR pipeline despite ongoing unprofitability and no expected profits in the next three years. Read more about this...